Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study
Yeung, David T, Shanmuganathan, Naranie, Reynolds, John, Branford, Susan, Walia, Mannu, Yong, Agnes S. M., Shortt, Jake, Burbury, Kate, Chee, Lynette C.Y., Viiala, Nick, Cunningham, Ilona, Ross, David M., D'Souza, Alwyn Bernard, Wright, Matthew P.F., Harrup, Rosemary Anne, Forsyth, Cecily, Filshie, Robin, Browett, Peter J., Lane, Steven W., Grove, Carolyn, Grigg, Andrew P, Hughes, Timothy P, ALLG, on Behalf Of The
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Survival of Patients with Multiple Myeloma in Western Australia, a Large State of 2.5 Million Square Kilometers: A Population Based Study
Ng, Teng Fong, Leahy, Michael F., Augustson, Bradley, Burrow, Sally, Vlaskovsky, Philip, Carnley, Ben, Wright, Matthew P.F.
Published in Blood (29.11.2018)
Published in Blood (29.11.2018)
Get full text
Journal Article
Prognostic Factors and the Impact of Frontline Therapy in Peripheral T-Cell Lymphoma: A Multicenter Australian Study
Kuzich, James Anton, Hutchison, Andrew Peter, Lim, Kenneth, Wright, Matthew P.F., Cull, Gavin, Leahy, Michael F., Joske, David John Longstaff, Radeski, Dejan, Purtill, Duncan
Published in Blood (08.12.2017)
Published in Blood (08.12.2017)
Get full text
Journal Article
Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study
Yeung, David T, Grigg, Andrew, Shanmuganathan, Naranie, Solterbeck, Ann Christine, White, Deborah L., Branford, Susan, Viiala, Nicholas, Rowlings, Philip Arthur, Mills, Anthony K, Shortt, Jake, Tiley, Campbell, Ross, David M, Kipp, David, Harrup, Rosemary Anne, Cunningham, Ilona, Kwan, John, Eek, Richard, Mutsando, Howard, Tan, Ken-Soon, Burbury, Kate, Wright, Matthew P.F., Hughes, Timothy P., ALLG, On Behalf of the
Published in Blood (13.11.2019)
Published in Blood (13.11.2019)
Get full text
Journal Article
Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb E.N.E.S.Tswift Study
Hiwase, Devendra K, Tan, Peter, D'Rozario, James, Taper, John, Powell, Anthony Richard, Irving, Ian, Wright, Matthew P.F., Branford, Susan, Yeung, David T., Anderson, Luke, Gervasio, Othon L, Hughes, Timothy P.
Published in Blood (02.12.2016)
Published in Blood (02.12.2016)
Get full text
Journal Article
Allogeneic Stem Cell Transplantation (allo-SCT) for Chronic Myelomonocytic Leukemia – a Multicentre Australian Experience: Prognostic Factors for Survival and Relapse
Bajel, Ashish R., Curley, Cameron, Lim, Andrew Boon Ming, Handunnetti, Sasanka, Getta, Bartlomiej, Thompson, Philip A, Wright, Matthew P.F., Greenwood, Matthew, Hertzberg, Mark S, Curtis, David J., Szer, Jeffrey, Kennedy, Glen A, Ritchie, David
Published in Blood (06.12.2014)
Published in Blood (06.12.2014)
Get full text
Journal Article